Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls

Anticancer Res. 2003 Mar-Apr;23(2A):851-3.


Background: The determination of Tumor M2 Pyruvate Kinase (Tumor M2-PK) in EDTA plasma has been described as a tumor marker in a variety of different tumor types. Since most GI tumors grow intraluminally, it appeared interesting to determine whether Tumor M2-PK is detectable in the feces of tumor patients.

Materials and methods: Measurements were performed with a commercially available ELISA (ScheBo Biotech AG, Giessen, Germany) modified for fecal analysis. Samples of controls, GI cancer and adenoma patients were tested.

Results: Fecal Tumor M2-PK concentrations could be quantified. A significant difference between cancer patients and controls was found. The highest concentrations were observed in colorectal cancer. However, fecal Tumor M2-PK was not detectable in 5 tumor patients.

Conclusion: The measurement of fecal Tumor M2-PK concentrations might provide an interesting screening tool for colorectal cancer. Further studies comparing the determination of Tumor M2-PK in stool to occult blood in stool are in progress.

Publication types

  • Comparative Study

MeSH terms

  • Adenoma / diagnosis*
  • Adenoma / enzymology
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / analysis*
  • Colorectal Neoplasms / diagnosis*
  • Colorectal Neoplasms / enzymology
  • Feces / chemistry*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pyruvate Kinase / analysis*
  • Reference Values
  • Stomach Neoplasms / diagnosis*
  • Stomach Neoplasms / enzymology


  • Biomarkers, Tumor
  • Pyruvate Kinase